Reliance Global Group宣布通过旗下Ezra生物科技部门，成功完成对处于研发后期的放射性药物创新企业Innervate的战略投资。此次投资标志着集团在生物科技领域布局的重要里程碑。
Innervate作为放射性药物领域的先锋企业，其创新技术平台与研发管线具有显著行业优势。通过本次资本运作，Reliance Global Group将深化在精准医疗赛道的战略布局，同时为Innervate的临床试验推进及商业化进程注入强劲动力。
这项投资不仅彰显了Reliance Global Group对生物科技产业前景的坚定信心，更凸显其通过资本赋能推动医疗创新的战略决心。双方将通过资源整合，共同加速突破性放射疗法的研发与应用，为全球患者提供更先进的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.